Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats

An animal model for Wilson disease

Uta Merle, Jens Enckea, Sabine Tuma, Martin Volkmann, Luigi Naldini, Wolfgang Stremmel

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective. Wilson disease is a copper storage disorder caused by mutations in the ATP7B gene leading to liver cirrhosis. It has previously been shown that lentiviral vectors can govern an efficient delivery and stable expression of a transgene. The aim of this pilot study was to prove the principle of a lentiviral gene transfer in the Long-Evans cinnamon (LEC) rat, an animal model of Wilson disease. Material and methods. LEC rats were treated either by systemic application of lentiviral vectors or by intrasplenic transplantation of LEC-rat hepatocytes lentivirally transduced with ATP7B. The ATP7B gene expression was analyzed by RT-PCR and immunofluorescence analysis. The therapeutic effect was assessed by analysis of liver histology, serum ceruloplasmin oxidase activity, and liver copper content. Results. Hepatic expression of the transgene was detected at different time-points post-treatment and lasted for up to 24 weeks (end of experiment). Liver copper levels were lowered in all treatment groups compared to untreated LEC rats. Twenty-four weeks after treatment, the area of the examined liver-tissue sections occupied by fibrosis was 48.3-57.9% in untreated LEC rats and 10.7-19.8% in rats treated with cell therapy. In systemically treated rats, only small fibrous septa could be observed. Conclusions. These data prove for the first time that lentiviral ATP7B gene transfer is feasible in Wilson disease. In our pilot study the systemic approach was more promising in ameliorating disease progression than the transplantation of lentivirally transduced hepatocytes.

Original languageEnglish
Pages (from-to)974-982
Number of pages9
JournalScandinavian Journal of Gastroenterology
Volume41
Issue number8
DOIs
Publication statusPublished - Aug 1 2006

Fingerprint

Inbred LEC Rats
Hepatolenticular Degeneration
Disease Progression
Animal Models
Liver
Copper
Genes
Transgenes
Hepatocytes
Transplantation
Ceruloplasmin
Therapeutic Uses
Cell- and Tissue-Based Therapy
Liver Cirrhosis
Fluorescent Antibody Technique
Histology
Fibrosis
Therapeutics
Gene Expression
Polymerase Chain Reaction

Keywords

  • Copper
  • LEC rat
  • Lentiviral gene therapy
  • Wilson disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats : An animal model for Wilson disease. / Merle, Uta; Enckea, Jens; Tuma, Sabine; Volkmann, Martin; Naldini, Luigi; Stremmel, Wolfgang.

In: Scandinavian Journal of Gastroenterology, Vol. 41, No. 8, 01.08.2006, p. 974-982.

Research output: Contribution to journalArticle

Merle, Uta ; Enckea, Jens ; Tuma, Sabine ; Volkmann, Martin ; Naldini, Luigi ; Stremmel, Wolfgang. / Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats : An animal model for Wilson disease. In: Scandinavian Journal of Gastroenterology. 2006 ; Vol. 41, No. 8. pp. 974-982.
@article{afafb113901c4e968b79cb1c237c1e0f,
title = "Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats: An animal model for Wilson disease",
abstract = "Objective. Wilson disease is a copper storage disorder caused by mutations in the ATP7B gene leading to liver cirrhosis. It has previously been shown that lentiviral vectors can govern an efficient delivery and stable expression of a transgene. The aim of this pilot study was to prove the principle of a lentiviral gene transfer in the Long-Evans cinnamon (LEC) rat, an animal model of Wilson disease. Material and methods. LEC rats were treated either by systemic application of lentiviral vectors or by intrasplenic transplantation of LEC-rat hepatocytes lentivirally transduced with ATP7B. The ATP7B gene expression was analyzed by RT-PCR and immunofluorescence analysis. The therapeutic effect was assessed by analysis of liver histology, serum ceruloplasmin oxidase activity, and liver copper content. Results. Hepatic expression of the transgene was detected at different time-points post-treatment and lasted for up to 24 weeks (end of experiment). Liver copper levels were lowered in all treatment groups compared to untreated LEC rats. Twenty-four weeks after treatment, the area of the examined liver-tissue sections occupied by fibrosis was 48.3-57.9{\%} in untreated LEC rats and 10.7-19.8{\%} in rats treated with cell therapy. In systemically treated rats, only small fibrous septa could be observed. Conclusions. These data prove for the first time that lentiviral ATP7B gene transfer is feasible in Wilson disease. In our pilot study the systemic approach was more promising in ameliorating disease progression than the transplantation of lentivirally transduced hepatocytes.",
keywords = "Copper, LEC rat, Lentiviral gene therapy, Wilson disease",
author = "Uta Merle and Jens Enckea and Sabine Tuma and Martin Volkmann and Luigi Naldini and Wolfgang Stremmel",
year = "2006",
month = "8",
day = "1",
doi = "10.1080/00365520600554790",
language = "English",
volume = "41",
pages = "974--982",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats

T2 - An animal model for Wilson disease

AU - Merle, Uta

AU - Enckea, Jens

AU - Tuma, Sabine

AU - Volkmann, Martin

AU - Naldini, Luigi

AU - Stremmel, Wolfgang

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Objective. Wilson disease is a copper storage disorder caused by mutations in the ATP7B gene leading to liver cirrhosis. It has previously been shown that lentiviral vectors can govern an efficient delivery and stable expression of a transgene. The aim of this pilot study was to prove the principle of a lentiviral gene transfer in the Long-Evans cinnamon (LEC) rat, an animal model of Wilson disease. Material and methods. LEC rats were treated either by systemic application of lentiviral vectors or by intrasplenic transplantation of LEC-rat hepatocytes lentivirally transduced with ATP7B. The ATP7B gene expression was analyzed by RT-PCR and immunofluorescence analysis. The therapeutic effect was assessed by analysis of liver histology, serum ceruloplasmin oxidase activity, and liver copper content. Results. Hepatic expression of the transgene was detected at different time-points post-treatment and lasted for up to 24 weeks (end of experiment). Liver copper levels were lowered in all treatment groups compared to untreated LEC rats. Twenty-four weeks after treatment, the area of the examined liver-tissue sections occupied by fibrosis was 48.3-57.9% in untreated LEC rats and 10.7-19.8% in rats treated with cell therapy. In systemically treated rats, only small fibrous septa could be observed. Conclusions. These data prove for the first time that lentiviral ATP7B gene transfer is feasible in Wilson disease. In our pilot study the systemic approach was more promising in ameliorating disease progression than the transplantation of lentivirally transduced hepatocytes.

AB - Objective. Wilson disease is a copper storage disorder caused by mutations in the ATP7B gene leading to liver cirrhosis. It has previously been shown that lentiviral vectors can govern an efficient delivery and stable expression of a transgene. The aim of this pilot study was to prove the principle of a lentiviral gene transfer in the Long-Evans cinnamon (LEC) rat, an animal model of Wilson disease. Material and methods. LEC rats were treated either by systemic application of lentiviral vectors or by intrasplenic transplantation of LEC-rat hepatocytes lentivirally transduced with ATP7B. The ATP7B gene expression was analyzed by RT-PCR and immunofluorescence analysis. The therapeutic effect was assessed by analysis of liver histology, serum ceruloplasmin oxidase activity, and liver copper content. Results. Hepatic expression of the transgene was detected at different time-points post-treatment and lasted for up to 24 weeks (end of experiment). Liver copper levels were lowered in all treatment groups compared to untreated LEC rats. Twenty-four weeks after treatment, the area of the examined liver-tissue sections occupied by fibrosis was 48.3-57.9% in untreated LEC rats and 10.7-19.8% in rats treated with cell therapy. In systemically treated rats, only small fibrous septa could be observed. Conclusions. These data prove for the first time that lentiviral ATP7B gene transfer is feasible in Wilson disease. In our pilot study the systemic approach was more promising in ameliorating disease progression than the transplantation of lentivirally transduced hepatocytes.

KW - Copper

KW - LEC rat

KW - Lentiviral gene therapy

KW - Wilson disease

UR - http://www.scopus.com/inward/record.url?scp=33745712832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745712832&partnerID=8YFLogxK

U2 - 10.1080/00365520600554790

DO - 10.1080/00365520600554790

M3 - Article

VL - 41

SP - 974

EP - 982

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 8

ER -